ATE422362T1 - Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose - Google Patents
Vakzine und verwendung davon zur behandlung amyotrophischer lateralskleroseInfo
- Publication number
- ATE422362T1 ATE422362T1 AT02788511T AT02788511T ATE422362T1 AT E422362 T1 ATE422362 T1 AT E422362T1 AT 02788511 T AT02788511 T AT 02788511T AT 02788511 T AT02788511 T AT 02788511T AT E422362 T1 ATE422362 T1 AT E422362T1
- Authority
- AT
- Austria
- Prior art keywords
- cop
- lateral sclerosis
- amyotrophic lateral
- vaccines
- treating amyotrophic
- Prior art date
Links
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 3
- 208000026072 Motor neurone disease Diseases 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 206010056677 Nerve degeneration Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33613901P | 2001-12-06 | 2001-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE422362T1 true ATE422362T1 (de) | 2009-02-15 |
Family
ID=23314742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02788511T ATE422362T1 (de) | 2001-12-06 | 2002-12-05 | Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7351686B2 (de) |
| EP (1) | EP1429800B1 (de) |
| JP (1) | JP4542339B2 (de) |
| KR (1) | KR20040081431A (de) |
| CN (2) | CN1617736A (de) |
| AT (1) | ATE422362T1 (de) |
| AU (1) | AU2002353486B2 (de) |
| CA (1) | CA2469092C (de) |
| CY (1) | CY1109044T1 (de) |
| DE (1) | DE60231131D1 (de) |
| DK (1) | DK1429800T3 (de) |
| ES (1) | ES2322566T3 (de) |
| HU (1) | HU228207B1 (de) |
| IL (1) | IL160105A0 (de) |
| IS (1) | IS2670B (de) |
| MX (1) | MXPA04005537A (de) |
| NO (1) | NO336231B1 (de) |
| NZ (1) | NZ533356A (de) |
| PL (1) | PL205469B1 (de) |
| PT (1) | PT1429800E (de) |
| RU (1) | RU2303996C2 (de) |
| SI (1) | SI1429800T1 (de) |
| WO (1) | WO2003047500A2 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7399740B2 (en) | 2001-06-28 | 2008-07-15 | Yeda Research And Development Co. Ltd. | Poly-Glu,Tyr for neuroprotective therapy |
| ES2386435T3 (es) * | 2003-01-07 | 2012-08-21 | Yeda Research And Development Co., Ltd. | Vacuna en forma de gotas oculares que contiene copolímero 1 para inmunización terapéutica |
| JP5456235B2 (ja) | 2003-11-12 | 2014-03-26 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 神経変性疾患を治療するためのワクチン及び方法 |
| JP4808631B2 (ja) | 2003-12-09 | 2011-11-02 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 精神医学的障害の治療用のコポリマー１を含む方法及びワクチン |
| EP1778286A4 (de) * | 2004-03-03 | 2009-04-08 | Teva Pharma | Kombinationstherapie mit glatiramer-acetat und riluzol |
| JP5495490B2 (ja) * | 2004-05-07 | 2014-05-21 | アレス トレーディング エスエイ | ランダム共重合体を用いる疾患の治療方法 |
| US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| JP5241012B2 (ja) * | 2005-07-15 | 2013-07-17 | ノバルティス アーゲー | Ｐａｍｐｓ、病原体関連分子パターン |
| CN100448481C (zh) * | 2006-06-22 | 2009-01-07 | 中国科学院遗传与发育生物学研究所 | xCT蛋白及其编码基因的新用途 |
| WO2009040814A1 (en) | 2007-09-24 | 2009-04-02 | Hadasit Medical Research Services & Development Ltd | Use of copolymer 1 for treatment of muscular dystrophy |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| CA2814500A1 (en) | 2010-10-11 | 2012-04-19 | Teva Pharmaceutical Industries Ltd | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| WO2012143924A1 (en) | 2011-04-21 | 2012-10-26 | Mapi Pharma Ltd. | Random pentapolymer for treatment of autoimmune diseases |
| HK1200274A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| US9861686B2 (en) * | 2011-12-05 | 2018-01-09 | Ben-Gurion University Of The Negev Research & Development Authority | Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (ALS) |
| WO2013144957A1 (en) * | 2012-03-26 | 2013-10-03 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression |
| WO2014037952A1 (en) | 2012-09-10 | 2014-03-13 | Yeda Research And Development Co. Ltd At The Weizmann Institute Of Science | Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| US3849650A (en) | 1973-03-29 | 1974-11-19 | Picker Corp | Automatic x-ray inspection system |
| IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| SE505316C2 (sv) | 1995-10-17 | 1997-08-04 | Kenneth G Haglid | Användning av proteinet S-100b för framställning av läkemedel för nervceller |
| RU2211697C2 (ru) * | 1996-09-27 | 2003-09-10 | Гилфорд Фармасьютикалз Инк. | Способ лечения глутаматных расстройств |
| EP1054880A1 (de) * | 1998-02-13 | 2000-11-29 | Autoimmune, Inc. | BEHANDLUNG VON MULTIPLER SKLEROSE MIT HILFE VON COP-1 UND Th2-VERSTÄRKENDEN CYTOKINEN |
| US20030108528A1 (en) * | 1998-05-19 | 2003-06-12 | Michal Eisenbach-Schwartz | Activated t-cells, nervous system-specific antigens and their uses |
| US20020072493A1 (en) * | 1998-05-19 | 2002-06-13 | Yeda Research And Development Co. Ltd. | Activated T cells, nervous system-specific antigens and their uses |
| WO1999060021A2 (en) | 1998-05-19 | 1999-11-25 | Yeda Research And Development Co. Ltd. | Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system |
| JP2002500199A (ja) | 1998-07-21 | 2002-01-08 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | 活性化ｔ細胞、及びそれらの用途 |
| WO2000005249A2 (en) | 1998-07-23 | 2000-02-03 | The President And Fellows Of Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
| RU2155063C1 (ru) * | 1999-10-20 | 2000-08-27 | Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" | Тетрапептид, стимулирующий функциональную активность нейронов, фармакологическое средство на его основе и способ его применения |
| JP4328050B2 (ja) * | 2000-01-20 | 2009-09-09 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用 |
| EP1294390B1 (de) * | 2000-06-07 | 2006-01-04 | YEDA RESEARCH AND DEVELOPMENT CO., Ltd. | Verwendung des copolymer-1 peptids sowie von damit verwandten peptiden und polypeptiden und von damit behandelten t-zellen zur neuroprotektion vor glutamattoxizitaet |
| WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| US6835711B2 (en) * | 2001-06-28 | 2004-12-28 | Yeda Research And Development Co. Ltd. | Use of poly-Glu,Tyr for neuroprotective therapy |
| US7399740B2 (en) * | 2001-06-28 | 2008-07-15 | Yeda Research And Development Co. Ltd. | Poly-Glu,Tyr for neuroprotective therapy |
-
2002
- 2002-12-05 US US10/485,576 patent/US7351686B2/en not_active Expired - Lifetime
- 2002-12-05 AT AT02788511T patent/ATE422362T1/de active
- 2002-12-05 PT PT02788511T patent/PT1429800E/pt unknown
- 2002-12-05 WO PCT/IL2002/000979 patent/WO2003047500A2/en not_active Ceased
- 2002-12-05 DK DK02788511T patent/DK1429800T3/da active
- 2002-12-05 JP JP2003548761A patent/JP4542339B2/ja not_active Expired - Fee Related
- 2002-12-05 CA CA2469092A patent/CA2469092C/en not_active Expired - Fee Related
- 2002-12-05 NZ NZ533356A patent/NZ533356A/en not_active IP Right Cessation
- 2002-12-05 PL PL370070A patent/PL205469B1/pl unknown
- 2002-12-05 KR KR10-2004-7008780A patent/KR20040081431A/ko not_active Ceased
- 2002-12-05 IL IL16010502A patent/IL160105A0/xx unknown
- 2002-12-05 SI SI200230800T patent/SI1429800T1/sl unknown
- 2002-12-05 DE DE60231131T patent/DE60231131D1/de not_active Expired - Lifetime
- 2002-12-05 HU HU0500039A patent/HU228207B1/hu not_active IP Right Cessation
- 2002-12-05 AU AU2002353486A patent/AU2002353486B2/en not_active Ceased
- 2002-12-05 EP EP02788511A patent/EP1429800B1/de not_active Expired - Lifetime
- 2002-12-05 RU RU2004120536/14A patent/RU2303996C2/ru not_active IP Right Cessation
- 2002-12-05 CN CNA028277015A patent/CN1617736A/zh active Pending
- 2002-12-05 ES ES02788511T patent/ES2322566T3/es not_active Expired - Lifetime
- 2002-12-05 CN CN201110056639.8A patent/CN102151330B/zh not_active Expired - Fee Related
- 2002-12-05 MX MXPA04005537A patent/MXPA04005537A/es active IP Right Grant
-
2004
- 2004-06-03 IS IS7296A patent/IS2670B/is unknown
- 2004-07-05 NO NO20042833A patent/NO336231B1/no not_active IP Right Cessation
-
2009
- 2009-05-06 CY CY20091100485T patent/CY1109044T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE422362T1 (de) | Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose | |
| DE69718150D1 (de) | Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien | |
| DE69400799D1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
| SE9302308L (sv) | Proteinberedning | |
| CY1110727T1 (el) | Παρασκευασματα θετικων κατα gram βακτηριων για τη θεραπεια ασθενειων που περιλαμβανουν μια ανοσολογικη δυσρυθμιση | |
| PL324531A1 (en) | Derivatives of cyclosporin effective against hiv virus | |
| ATE347376T1 (de) | Behandlung von allergien | |
| DE60233898D1 (de) | Transdermales therapeutisches system für parkinson-krankheit mit hohen rotigotin-plasmaspiegeln | |
| DE69730476D1 (de) | Albumin als aktiven bestandteil zur behandlung von bindehaut- und hornhautverletzungen und von trockenen augen | |
| DE69628844D1 (de) | Leishmania-antigene zur anwendung in der leishmaniasis therapie und diagnose | |
| EP1958960A3 (de) | Verfahren für die Herstellung einer nicht-toxischen Anthrax-Impfung | |
| MXPA02005563A (es) | Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma. | |
| PT1015595E (pt) | Peptidos derivados da proteina de ligacao (g) do virus sincicial respiratorio | |
| BR0211970A (pt) | Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca | |
| AR005750A1 (es) | Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion | |
| NO20034453L (no) | Anvendelse av CD25-bindende molekyler i steroid-resistente pasienter | |
| ATE415419T1 (de) | Inaktivierte zytokine zur immunisierung | |
| ATE296640T1 (de) | Methode und mittel zur behandlung eines post- poliosyndroms | |
| ATE349532T1 (de) | Zytotoxisches t-zellepitop des papillomavirus l1- proteins und seine verwendung in diagnostik und therapie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1429800 Country of ref document: EP |